Early studies of terminal transferase (TdT) expression in acute leukemia indicated that this enzyme is only found in acute leukemia of lymphoblastic type (ALL). More recently, however, several reports have suggested that TdT-positive blast cells may be found in a substantial number of cases of acute myeloid leukemia (AML). In this study, a sensitive immunoalkaline phosphatase procedure (the APAAP technic) has been used to stain normal and neoplastic blood and bone marrow samples for TdT with the use of both polyclonal and monoclonal anti-TdT antibodies. As expected, most cases of ALL studied (63 of 65) were TdT-positive. In addition, however, blast cells in 22 out of 59 (37%) cases of AML were stained by anti-TdT antibodies. Both nuclear and cytoplasmic localization were seen in each type of acute leukemia. These findings, together with previous immunocytochemical and biochemical studies, suggest that a substantial number of cases of AML express TdT (usually in a minority of blast cells) and that the frequency with which these cases are detected is directly related to the sensitivity of the staining technic used.
TERMINAL DEOXYNUCLEOTIDYL TRANSFER-ASE (TdT) has been widely used as a marker for the diagnosis and classification of acute leukemia. 3 ' 9,28 Its use for this purpose stemmed from reports that it was present at high levels in T-cell and common acute lymphoblastic leukemia (ALL) but absent from the neoplastic cells of acute myeloblasts leukemia (AML).' 92 ' Terminal transferase is usually detected biochemically or immunocytochemically by an indirect immunofluorescent technic, 38 applied to methanol-fixed cell smears, although a number of more recent papers have described the use of immunoperoxidase procedures as an alternative.
61315 ' 622 -31 - 34 -37 Initial studies of TdT in leukemia suggested that there were no exceptions to the rule that ALLs are TdT-positive and AMLs are TdT-negative. However, by 1982 several laboratories had reported cases of AML in which the blast cells gave positive immunocytochemical reactions for TdT.'-5 ' 7 ' 9 ' 23 ' 28 - 39 It was not generally accepted that these cases were classic examples of AML, and it was thought that they represented misdiagnosed cases of ALL. The statement by Jani and associates,' 8 based upon a review of more than 300 cases of acute leukemia, that true TdT-positive AML cases are "very infrequent" reflected the prevailing view.
The belief that TdT is virtually specific as a marker for leukemias of lymphoblastic origin has recently been challenged by a number of reports. 22 - 29 ' 36 The most recent of these (published last year in this Journal) 22 reported that TdT immunoreactivity could be found in 6 out of 13 (46%) cases of AML with the use of immunoperoxidase labeling technics. Because these reports are in direct opposition to the conventional view concerning TdT expression in acute leukemia, we have reviewed our results obtained with the use of a new and sensitive immunoalkaline phosphatase technic (the APAAP procedure) to stain samples from 131 cases of acute leukemia for TdT immunoreactivity. The results obtained in this study indicate that TdT antigenic reactivity is detectable in the neoplastic cells in about one-third of cases of AML, and suggest that the frequency of its detection in this disease may reflect the sensitivity of the immunocytochemical procedure used.
Patients and Methods

Hematologic Samples
Blood and bone marrow samples were obtained from patients attending the Hematology Department of the John Radcliffe Hospital or were referred from hospitals in the Oxford region. The diagnosis in all cases was based upon conventional hematologic criteria and immunophenotyping using a panel of monoclonal antibodies. 10 For cases of AML the diagnosis was made on the basis of the morphologic appearance of the blast cells (according to the French-American-British [FAB] classification), Sudan black or peroxidase positivity, the expression of myeloid antigens (e.g., myeloperoxidase and monocytic antigens), and the lack of markers present on lymphoid cells (e.g., CALLA, T-and B-cell antigens). Cases of AML of FAB subtypes Ml, M2, M3, M4, and M5 were included in the study.
Staining was performed either on routinely prepared marrow and blood smears or on cytocentrifuge preparations of mononuclear cells separated by gradient centrifugation on Lymphoprep® (Nyegaard). Smears and cytocentrifuge preparations were air dried and stored at -20 °C until the time of immunocytochemical labeling.
Fresh human thymus tissue samples (obtained during cardiac surgery) were snap-frozen and cryostat sectioned. Frozen sections were then air dried and stored at -20 °C. Cytocentrifuge preparations were made from the TdT-positive cell line NALM-1 and from TdT-negative cell lines (e.g., Daudi) and stored as for blood and bone marrow smears.
Immunocytochemical Reagents
Sheep antimouse Ig, monoclonal mouse antirabbit Ig, and monoclonal APAAP complexes were prepared in the authors' laboratory. 9 Rabbit antimouse Ig and alkaline phosphatase conjugated swine antirabbit Ig were obtained from Dakopatts a/s. Affinity purified rabbit anti-TdT and monoclonal mouse anti-TdT (HTdT-1) were obtained from Supertechs, Inc., or were kindly donated by Dr. F. Bollum. All reagents were diluted before use in TRIS buffer, pH 7.6, 0.05 M (TBS).
Immunocytochemical Staining
TdT Staining. Slides were warmed to room temperature and then fixed (in most experiments) in methanol for 15 minutes at 4 °C. In addition, the following alternative fixation schedules were evaluated: (1) buffered formal acetone 26 at room temperature for 30 seconds; (2) formalin methanol (1:9) for 10 seconds at room temperature; (3) acetone at room temperature for 10 minutes; (4) methanol for 60 seconds at room temperature; (5) ethanol for 60 seconds at room temperature; and (6) acetone:methanol (1:1) for 60 seconds at room temperature.
Slides were transferred after fixation (without drying) to TBS, except after acetone fixation, when slides were allowed to air dry.
Slides were stained for TdT, with the use of either polyclonal or monoclonal anti-TdT, by the APAAP or alkaline phosphatase (AP) conjugate technics (detailed in Table 1 ). Most results reported in this article were obtained with the use of the polyclonal reagent (because the monoclonal antibody was only available in the latter stages of this investigation). Slides were counterstained with hematoxylin and mounted in an aqueous mounting medium.
Immunophenotyping. Cell smears were stained with monoclonal antibodies against white blood cell and leukemia-associated antigens by the APAAP technic, as described previously. Controls. Negative control samples included normal peripheral blood mononuclear cell preparations and TdT-negative cell lines stained by the APAAP or indirect AP conjugate technic for TdT. Furthermore, in some experiments rabbit anti-TdT was replaced by normal rabbit serum (diluted between 1/250 and 1/2,500), or the anti-TdT or subsequent antibodies (see Table 1 ) were omitted completely from the staining procedure. Omission of the primary antibody was also used as a negative control when labeling with monoclonal antiTdT. The NALM-1 cell line was used as a TdT-positive control.
Results
The two immunoalkaline phosphatase technics (APAAP and the indirect AP-conjugate procedure) gave All results refer to the number of positive cases/number of cases tested (%).
Normal Thymus and Bone Marrow
Cryostat sections of thymus showed strong labeling of cortical areas, with little or no labeling in the medulla (Fig. 1) . Staining of bone marrow smears from normal persons revealed intensely labeled cells present in low numbers, particularly in marrow samples from children (Fig. 2) . Many of these cells resembled intermediatesized lymphoid cells, but some contained nuclei with irregular outlines or clefts. In addition, all marrow samples contained megakaryocytes showing cytoplasmic labeling of variable intensity (Fig. 2) . No staining was seen when normal peripheral blood mononuclear cells were stained.
strong staining of TdT in cell smear preparations and on thymus sections, the vivid red reaction product contrasting with the blue nuclear counterstain (Figs. 1, 2, 5-8). However, the labeling reactions obtained with the indirect two-stage AP-conjugate staining method were consistently weaker than those observed with the multilayer APAAP technic. Staining reactions obtained with the monoclonal anti-TdT antibody were essentially identical to those obtained with the polyclonal reagent, although the monoclonal antibody consistently gave weaker labeling reactions (despite the use of a multilayer immunoenzymatic procedure [ Table 1 ]).
Acute Leukemia
The results of staining 131 cases of acute leukemia for TdT are summarized in Table 2 
47
frequent staining pattern was a coarsely granular labeling of the nuclei (Figs. 5 and 6 ), but, in addition, diffuse cytoplasmic staining was often seen. In a few cases labeling was restricted to the cytoplasm, and cells in mitosis always gave strong cytoplasmic reactivity.
Acute Undifferentiated Leukemia (AUL).
Seven cases of AUL all showed TdT positivity by the APAAP technic (Table 2) , both nuclear and cytoplasmic labeling being seen (Fig. 3) .
Acute Myeloid Leukemias. TdT-positive blast cells were found (using polyclonal anti-TdT) in 22 of the 59 (37%) samples of AML studied by the APAAP method and 4 of 17 (24%) samples studied by the indirect AP method ( Table 2 , Figs. 7 and 8 ). TdT-positive AML cases were also detected with the use of monoclonal anti-TdT (11 of 33 cases) and the APAAP technic ( Table  2) . As in ALL, both nuclear and cytoplasmic patterns of TdT staining were seen. There was great variability in the number of TdT-positive blast cells (10-90%) (Fig. 4) , but the percentage of positive cells was usually lower than in ALL and the intensity of the labeling reaction usually weaker. The intensity of the staining was always strongest when polyclonal anti-TdT and the APAAP technic were used.
Technical Aspects of TdT Staining
Fixation. TdT antigen could be detected in NALM-1 cells and acute leukemic samples after fixation by each of the different schedules evaluated (see "Methods"), although formalin-containing fixatives gave weaker reactions. The best combination of cell morphology and antigenic reactivity was obtained with cold (4 °C) methanol fixation for 15 minutes. Acetone fixation for 10 minutes at room temperature was the optimal fixative for staining thymus sections.
Storage. TdT antigen could be detected in slides that had been kept for up to one week at room temperature. Slides stored at -20 °C retained immunocytochemical reactivity for periods of up to one year. There was no difference in the intensity of the label or distribution (i.e., nuclear or cytoplasmic) of the TdT between freshly labeled samples and those restained after storage for long periods (up to two years) at -20 °C.
Discussion
This study indicates that immunoalkaline phosphatase staining by the APAAP method can be used to demonstrate TdT in neoplastic human white blood cells. This extends previous investigations from this laboratory on the use of the APAAP procedure to demonstrate a wide range of cellular markers (e.g., T-and B-cell-associated antigens, HLA-DR, CALLA, etc.) in hemato-^ ' 30 This technic avoids problems resulting from endogenous peroxidase activity and in consequence new cases of leukemia are routinely phenotyped in this laboratory by APAAP staining of air-dried blood and bone marrow smears using polyclonal antiTdT in combination with a panel of monoclonal reagents. 10 A recent article in this Journal has independently confirmed the value of the APAAP technic for phenotyping cases of acute leukemia. 32 An unexpected finding in this study was the high number of cases of AML (37%) in which blast cells were reactive with anti-TdT antibodies. Positive labeling reactions on AML cases were obtained with the use of both the monoclonal and polyclonal anti-TdT, so that this is unlikely to represent spurious reactivity caused by the presence of nonspecific antibodies in the polyclonal reagent. TdT-positive AML cases were detected both by the indirect AP-conjugate labeling method (24%) and by the APAAP technic, but more positive cases and a larger number of positive cells were detected by the latter method ( Table 2 ), suggesting that the APAAP method is the more sensitive of the two labeling procedures.
Although initial studies suggested that cases of TdTpositive AML were "exceedingly rare," 3 a number of investigators have now clearly documented this phenomenon (Table 3 ). The highest frequency has been reported in a recent study by Lanham and associates 22 in which immunoperoxidase labeling technics revealed TdT positivity (in more than 10% of cells) in 46% of AML cases. It is of interest that when the same cases were studied by immunofluorescent labeling, TdT was revealed in only 15% of AML samples. It thus appears probable that the high incidence of TdT immunoreactivity in AML both in this study (37%) and in the report of Lanham and associates 22 (46%) results from the greater sensitivity of the four-stage APAAP method and the three-stage IP technic compared with two-stage indirect labeling procedures.
There is independent evidence, albeit indirect, from two sources for this concept that the frequency of TdT expression in AML reflects the sensitivity of the detec- This study is a summary of 12 previously published reports.
ERBER AND MASON
Twenty percent of cases contained more than 5% TdTpositive nucleated cells; 50% contained lower numbers of TdT-positive cells.
The value of 20% represents cases with high and intermediate levels; inclusion of cases with lower levels gives an incidence of 29%. Eleven percent of cases contained more than 10% positive cells; 14% more than 5% positive cells.
These results refer to more than 10% positive blast cells; 31% of AML cases had more than 40% TdT-positive cells (using IP methods). tion system. First, enzymatic assay of TdT suggests that there is a continuous spectrum of TdT activity in cases of AML, ranging from undetectable levels to values comparable to those found in ALL. 20 ' 2936 Second, previously reported figures for the frequency of TdT-positive AML cases (see Table 3 ) show marked variation, suggesting interlaboratory differences in the sensitivity of TdT detection.
It may also be noted that the reported frequencies of TdT-positive AML cases are dependent on the percentage of positive blast cells taken as a cut-off value. Lanham and colleagues, 22 using an IP method, found that one-third of AML cases (31%) had greater than 40% TdT-positive blasts, but that almost half of the cases of this type of leukemia (46%) had greater than 10% TdTpositive leukemic cells. Similarly, Bradstock and associates 5 found 13 cases (among 64 cases of ANLL) in which more than 5% of nucleated cells were TdT positive (a frequency of 20%), but that in an additional 19 cases smaller numbers of cells contained the enzyme. Inclusion of these latter cases gave an overall incidence (50%) comparable to the value obtained by Lanham and co-workers. 22 Jani and associates 18 also described an equivocal group of patients with TdT detectable in 5-10% of nucleated cells. Use of a more sensitive detection system in such borderline cases would tend to increase the number of blast cells scored as being TdT positive and hence the apparent incidence of TdT expression in AML.
TdT expression in AML has often been explained on the grounds that two neoplastic cell populations are present (one myeloid and the other lymphoid) or that TdT is aberrantly expressed by leukemic myeloblasts as a result of malignant transformation. It is not clear at present which of these two theories is correct. The former "bioclonal" hypothesis cannot explain cases in which it is clear (either on numeric grounds or from double labeling or other technics) that individual blast cells express both myeloperoxidase and TdT. 4, 7, 18, 22, 24 Even when double labeling of TdT-positive AML cases reveals that TdT is not expressed in the same cells as myeloid markers, 13 ' 33 it is possible that the two markers are nonetheless present in the same malignant clone and that TdT disappears before the maturation stage at which myeloperoxidase is first expressed. It may also be noted that theories postulating dual blast cell populations in TdT-positive AML 27, 28 are open to the objection that the putative lymphoid blast cells present in such cases do not express common ALL antigen. 18 Consequently, we favor the hypothesis that TdT positivity in AML represents, in at least a proportion of cases, the expression of this enzyme by malignant myeloblasts. It may be of relevance that cases of AML showing Ig gene rearrangement (initially considered a B-cellspecific phenomenon) have been reported. 35 Because TdT probably plays an important role in the generation of antibody diversity during Ig gene rearrangement, it is possible that similar mechanisms account for both This study revealed varying combinations of nuclear and cytoplasmic labeling in TdT-positive blast cells. The enzyme is traditionally thought of as being restricted to the cell nucleus, although a few publications refer to it as also being demonstrable in the cell cytoplasm by immunocytochemical staining. ' 34 It has also been noted that cells in mitosis show extensive cytoplasmic staining 22 and that megakaryocytes often show strong cytoplasmic TdT reactivity. 14 The fact that the enzyme is sometimes present within the cytoplasm is probably appreciated more readily with the use of immunoenzymatic procedures than immunofluorescence technics in which nuclear counterstaining is not utilized. The significance of cytoplasmic TdT is uncertain, but it may represent degradation products of the enzyme (detected by both the polyclonal and monoclonal anti-TdT antibodies). Alternatively, cytoplasmic TdT may be present in those cells that have recently undergone division.
In conclusion, this study indicates that immunoalkaline phosphatase labeling of TdT by the sensitive APAAP procedure is well suited to the routine laboratory diagnosis of leukemia, because the technic can be applied directly to bone marrow or blood smears and provides a permanent record in which both TdT-positive and -negative cells are clearly seen. The fact that this sensitive technic reveals a higher frequency of TdT-positive AML cases than has been reported in most previous studies entails no alteration in diagnostic decision making, given that the existence of such cases is already well documented. The presence of TdT thus remains of secondary importance in the classification of acute leukemia. In contrast, absence of TdT remains a highly significant finding in that it virtually excludes a diagnosis of lymphoblastic leukemia.
